US EditionCompound Treats Atherosclerosis and Fatty Liver Disease in Primate Model
Summary by Inside Precision Medicine
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Compound Treats Atherosclerosis and Fatty Liver Disease in Primate Model
A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis in primate models. A new study by a Chinese team and collaborators finds that DT-109 limits the formation of atherosclerotic plaques in both the aorta and coronary arteries of nonhuman primates. This glycine-based tripeptide also stopped critical processes that lead to vascular calcification, a significant catalyst of arterial stiffening and p…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
